MedPage Today  |  July 28, 2017

Eric Lindblom, JD, former director of the FDA Center for Tobacco Products’ Office of Policy, was highly critical of the FDA’s action to delay regulatory action on e-cigarettes, calling it “seriously troubling” in a press statement.

“If the FDA were truly concerned about protecting the public health, the agency would not extend the deadlines at all, or it would at least extend the deadlines only for those e-cigarettes and cigars that meet certain minimum standards and only for those smaller tobacco companies that might not have sufficient resources to meet the existing deadlines,” he said.

Read more here.